[SCHEDULE 13G/A] Theriva Biologics, Inc. SEC Filing

Rhea-AI Filing Summary

Empery Asset Management and two managing members filed an amended Schedule 13G reporting beneficial ownership of 504,091 shares of Theriva Biologics (TOVX), equal to 4.99% of the class. The reported shares are issuable upon exercise of warrants and are subject to a 4.99% Beneficial Ownership Limitation (the “Blocker”).

The filers report shared voting and dispositive power over 504,091 shares and no sole power. The ownership percentage is calculated using 9,597,952 shares outstanding as of August 7, 2025, as disclosed in the company’s Form 10‑Q. The filing certifies the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control.

Insights

Securities ownership & disclosure analyst

Passive 4.99% stake via warrants, capped by a blocker.

Empery Asset Management reports beneficial ownership of 504,091 Theriva Biologics shares, representing 4.99% of the class. The position reflects shares issuable upon warrant exercise and is constrained by a 4.99% Beneficial Ownership Limitation, which prevents exercises that would push ownership above that level.

The filing lists shared voting and dispositive power over 504,091 shares and no sole power. The percentage uses 9,597,952 shares outstanding as of August 7, 2025. The certification states the holdings are in the ordinary course and not to influence control.

This is an administrative ownership update; market impact depends on holder activity and warrant exercise mechanics disclosed. Subsequent filings may provide detail if ownership changes.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Theriva Biologics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

87164U508

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 87164U508

1

Names of Reporting Persons

Empery Asset Management, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 504,091.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 504,091.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

504,091.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

IA, PN

Comment for Type of Reporting Person: Includes 504,091 shares of Common Stock issuable upon exercise of the Warrants (as defined in Item 2(a)).

SCHEDULE 13G

CUSIP No. 87164U508

1

Names of Reporting Persons

Ryan M. Lane

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 504,091.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 504,091.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

504,091.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Includes 504,091 shares of Common Stock issuable upon exercise of the Warrants.

SCHEDULE 13G

CUSIP No. 87164U508

1

Names of Reporting Persons

Martin D. Hoe

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 504,091.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 504,091.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

504,091.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Includes 504,091 shares of Common Stock issuable upon exercise of the Warrants.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Theriva Biologics, Inc.
(b)	Address of issuer's principal executive offices: 9605 Medical Center Drive, Suite 270, Rockville, MD 20850
Item 2.
(a)	Name of person filing: This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons," with respect to Common Stock, par value $0.001 per share (the "Common Stock") issuable upon exercise of warrants (the "Warrants") of Theriva Biologics, Inc., a Nevada corporation (the "Company"): (i) Empery Asset Management, LP (the "Investment Manager"), with respect to the issuable upon exercise of the Warrants held by funds to which the Investment Manager serves as investment manager (the "Empery Funds"); (ii) Mr. Ryan M. Lane ("Mr. Lane"), with respect to the Common Stock issuable upon exercise of the Warrants held by the Empery Funds; and (iii) Mr. Martin D. Hoe ("Mr. Hoe"), with respect to the Common Stock issuable upon exercise of the Warrants held by the Empery Funds. The Investment Manager serves as the investment manager to each of the Empery Funds. Each of Mr. Lane and Mr. Hoe (the "Reporting Individuals") is a Managing Member of Empery AM GP, LLC (the "General Partner"), the general partner of the Investment Manager.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is: 1 Rockefeller Plaza, Suite 1205 New York, New York 10020
(c)	Citizenship: Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 87164U508
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 9,597,952 shares of Common Stock outstanding as of August 7, 2025, as reported in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2025, and assumes exercise of the Warrants (subject to the Blocker (as defined below)). Pursuant to the terms of the Warrants, the Reporting Persons cannot exercise the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the "Blocker"), and the shares of Common Stock listed as beneficially owned in Rows 6, 8 and 9 of the cover page for each Reporting Person and the percentage set forth in Row 11 of the cover page for each Reporting Person give effect to the Blockers. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Warrants due to the Blocker. The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all of the Common Stock issuable upon exercise of the Warrants (subject to the Blocker) held by the Empery Funds. Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all of the Common Stock issuable upon exercise of the Warrants (subject to the Blocker) held by the Empery Funds. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the Common Stock owned by another Reporting Person. Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such Common Stock.
(b)	Percent of class: 4.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Empery Asset Management, LP

Signature:	/s/ Ryan M. Lane
Name/Title:	By: Empery AM GP, LLC, its General Partner, By: Ryan M. Lane, its Managing Member
Date:	10/21/2025

Ryan M. Lane

Signature:	/s/ Ryan M. Lane
Name/Title:	Ryan M. Lane, individually
Date:	10/21/2025

Martin D. Hoe

Signature:	/s/ Martin D. Hoe
Name/Title:	Martin D. Hoe, individually
Date:	10/21/2025

FAQ

What stake in TOVX does Empery Asset Management report in this 13G/A?

They report 504,091 shares, representing 4.99% of Theriva Biologics’ common stock.

Are the reported TOVX shares currently outstanding or issuable?

They are issuable upon exercise of warrants, subject to a 4.99% Blocker.

What ownership powers does Empery report over TOVX shares?

They disclose shared voting power: 504,091 and shared dispositive power: 504,091; sole power: 0.

What share count was used to calculate Empery’s TOVX ownership percentage?

The calculation uses 9,597,952 shares outstanding as of August 7, 2025 from the company’s Form 10‑Q.

Is Empery’s TOVX position intended to influence control?

No. The certification states the securities were acquired and are held in the ordinary course, not to influence control.

Who are the reporting persons in this TOVX Schedule 13G/A?

Empery Asset Management, LP, and individuals Ryan M. Lane and Martin D. Hoe.